The National Multiple Sclerosis (MS) Society in the US is planning to invest $10.5m to support 42 new MS research projects.

The projects are part of a research strategy, which is aimed to stop MS, restore function that has been lost for patients with MS, and end the disease forever.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

MS is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.

"These new research investments are intended to answer questions that will accelerate breakthroughs."

Its symptoms range from numbness and tingling to blindness and paralysis, and most people with the disease are diagnosed between the ages of 20 and 50.

National Multiple MS Society’s latest investment is part of a projected investment of $50m for this year to support more than 380 new as well as ongoing studies across the globe.

Research projects include five studies that are exploring various aspects that relate to promoting the repair of nerve-insulating myelin to restore function in MS; a study carried out in Ohio, US to explore whether increasing physical activity levels can help reverse cognitive problems.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Other projects are conducting a study at Mt Sinai, testing a dietary approach to treat the disease, and two policy studies looking at factors driving the escalating costs of MS medications.

National MS Society research executive vice-president Bruce Bebo said: “These new research investments are intended to answer questions that will accelerate breakthroughs that change the world for people with MS.”

In order to find the best research, the society depends on more than 130 scientists who evaluate hundreds of proposals every year.

Funded by National MS Society, the research paved the way for existing therapies and continues to be a driving force of MS research.


Image: Photomicrograph of a demyelinating MS-Lesion. Photo: courtesy of Marvin 101.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact